Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · interferon and immune responses · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (70)
Show source-provided references
1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J. hepatol. 69(2018) 182-236.10.1016/j.jhep.2018.03.019 ↗
2. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases10.1002/hep.29913 ↗
3. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up10.1148/radiol.12111851 ↗
4. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses10.1158/0008-5472.CAN-05-2244 ↗
5. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy10.1016/j.canlet.2018.02.024 ↗
6. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note10.1200/JCO.2005.03.2334 ↗
7. Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis10.1016/j.biopha.2019.108764 ↗
8. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response10.1053/j.gastro.2009.12.051 ↗
9. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor10.1158/1078-0432.CCR-15-1352 ↗
10. Palliative radiofrequency ablation accelerates the residual tumor progression through increasing tumor-infiltrating MDSCs and reducing T-cell-mediated anti-tumor immune responses in animal model10.3389/fonc.2020.01308 ↗
11. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response10.1136/jitc-2020-001038 ↗
12. Cancer immunoediting: from immunosurveillance to tumor escape10.1038/ni1102-991 ↗
13. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma10.1186/s40425-016-0129-x ↗
14. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
15. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy10.1186/s12885-019-6073-7 ↗
16. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb consign study10.1634/theoncologist.2018-0072 ↗
17. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors10.1002/hep.31840 ↗
18. KEYNOTE-240 investigators, Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial10.1200/JCO.19.01307 ↗
19. STING-dependent cytosolic dna sensing mediates innate immune recognition of immunogenic tumors10.1016/j.immuni.2014.10.017 ↗
20. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors10.1016/j.immuni.2014.10.019 ↗
21. An inhalable nanoparticulate sting agonist synergizes with radiotherapy to confer long-term control of lung metastases10.1038/s41467-019-13094-5 ↗
22. STING pathway expression identifies NSCLC with an immune-responsive phenotype10.1016/j.jtho.2020.01.009 ↗
23. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral sting pathway activation in BRCA-deficient models of triple-negative breast cancer10.1158/2159-8290.CD-18-1218 ↗
24. Heat-based tumor ablation: role of the immune response10.1007/978-3-319-22536-4_8 ↗
25. STING activation in cancer immunotherapy10.7150/thno.37574 ↗
26. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity10.1126/sciadv.abc3646 ↗
27. Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma10.1038/s41551-021-00803-z ↗
28. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy10.1016/j.biomaterials.2020.120636 ↗
29. Dual-sensitive PEG-sheddable nanodrug hierarchically incorporating PD-L1 antibody and zinc phthalocyanine for improved immuno-photodynamic therapy10.1021/acsami.0c20422 ↗
30. cGAS-STING and cancer: dichotomous roles in tumor immunity and development10.1016/j.it.2017.07.013 ↗
31. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
32. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors10.1158/2159-8290.CD-13-0310 ↗
33. Supramolecular photothermal nanomedicine mediated distant tumor inhibition via PD-1 and TIM-3 blockage10.3389/fchem.2020.00001 ↗
34. The immune contexture in cancer prognosis and treatment10.1038/nrclinonc.2017.101 ↗
35. Understanding the tumor immune microenvironment (TIME) for effective therapy10.1038/s41591-018-0014-x ↗
36. Innate immune recognition of cancer10.1146/annurev-immunol-032414-112043 ↗
37. Activation of STING requires palmitoylation at the Golgi10.1038/ncomms11932 ↗
38. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy10.1016/j.ccell.2017.04.003 ↗
39. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells10.1038/ncomms16073 ↗
40. Dendritic cells in cancer immunology and immunotherapy10.1038/s41577-019-0210-z ↗
41. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity10.1016/j.celrep.2015.04.031 ↗
42. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis10.1038/s41586-018-0629-6 ↗
43. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities10.1182/blood.V98.10.3022 ↗
44. Core-shell distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy10.1021/acsnano.9b02149 ↗
45. The relevance of tumour pH to the treatment of malignant disease10.1016/S0167-8140(84)80077-8 ↗
46. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation10.1016/j.intimp.2018.10.035 ↗
47. Lysosomes: fusion and function10.1038/nrm2217 ↗
48. Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy10.1002/smll.201906832 ↗
49. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κb inhibitor for antitumor immunotherapy10.1126/sciadv.aay7785 ↗
50. Bioresponsive materials10.1038/natrevmats.2016.75 ↗
51. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
52. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system10.1038/nature03794 ↗
53. Facile generation of tumor-pH-labile linkage-bridged block copolymers for chemotherapeutic delivery10.1002/anie.201509507 ↗
54. A polymer-calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy10.1016/j.jconrel.2021.10.030 ↗
55. Biodegradable long-circulating polymeric nanospheres10.1126/science.8128245 ↗
56. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake10.1021/ja2084338 ↗
57. Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation10.1021/acsnano.8b04947 ↗
58. Regulatory T cells and immune tolerance10.1016/j.cell.2008.05.009 ↗
59. Type I interferons directly inhibit regulatory t cells to allow optimal antiviral t cell responses during acute LCMV infection10.1084/jem.20131556 ↗
60. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood10.1038/ni.2496 ↗
61. The TNF cytokine family: one track in a road paved by many10.1016/j.cyto.2013.05.027 ↗
62. Cytokines in cancer immunotherapy10.3390/cancers3043856 ↗
63. American society of clinical oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer10.1200/JCO.2009.23.4450 ↗
64. Quality improvement guidelines for radiofrequency ablation of liver tumours10.1007/s00270-009-9736-y ↗
65. Society of interventional radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors10.1016/j.jvir.2009.04.029 ↗
66. Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge10.1136/jitc-2020-000532 ↗
67. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor10.1080/19420862.2015.1136043 ↗
68. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy10.1002/adbi.201600013 ↗
69. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation10.1038/s41388-018-0169-4 ↗
70. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways10.1186/1479-5876-11-273 ↗